Compare iShares MSCI Indonesia ETF (EIDO) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Indonesia ETF vs TransMedics Group Inc — how do they compare? iShares MSCI Indonesia ETF trades at $11.89 (market cap $409.22M), while TransMedics Group Inc trades at $77.87 (market cap $2.74B). The key difference: TransMedics Group Inc is far larger — about 6.7× iShares MSCI Indonesia ETF's market cap, and TransMedics Group Inc is more actively traded (949,331 versus 879,527). Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Indonesia ETF for 76 Days and TransMedics Group Inc for 24 Days on average.
| EIDO | TMDX | |
|---|---|---|
Market Cap | $409.22M | $2.74B |
Volume | 879,527 | 949,331 |
52-Week High | $19.22 | $150.42 |
52-Week Low | $10.80 | $61.99 |
Typical Hold Time | 76 Days | 24 Days |
Sector | — | Health |
Enterprise Value | — | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EIDO trades at $11.67, down 1.6% on the day, with technical indicators showing a bearish trend as moving averages signal strong selling pressure. The ETF's financial ratios are not disclosed in available data, but recent news highlights its exposure to Indonesian equities and a challenging technical downtrend. Trading volume remains active, though recent sessions show a decline from average levels.
The outlook for EIDO is cautious due to weak price action and sector concentration risks, with limited upside from low earnings growth. Key risks include dependence on financials and commodity markets, while potential opportunities may arise from seasonal trends or valuation rebounds if investor sentiment improves.
TMDX trades at $79.00, down 2.55% amid bearish technical signals. The stock shows strong profitability with 22.69% net margin and 36.28% ROE, though recent earnings misses and margin compression from 2025 to 2026 raise concerns. Analyst consensus remains bullish with a $99.75 price target, but multiple legal investigations into fiduciary duties create uncertainty. Revenue growth continues with 2026 guidance at $668M.
The stock presents a growth opportunity with analyst upside potential, but faces near-term headwinds from earnings volatility and legal scrutiny. Execution on 2026 guidance and resolution of governance concerns will be critical for sustained momentum. Current valuation at 20.47 P/E appears reasonable given growth prospects if operational targets are met.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares MSCI Indonesia ETF
The fund generally will invest at least 80% of its assets in the component securities of the underlying index and in investments that have economic characteristics that are substantially identical to the component securities of the underlying index. The index is a free float-adjusted market capitalization-weighted index that is designed to measure the performance of the large-, mid- and small-capitalization segments of the equity market in Indonesia. The fund is non-diversified.
Read more on EIDO →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
